Qiagen

QGEN

Market cap $9.72B

Qiagen N.V. (QGEN) Presents at 44th Annual J.P.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028. Following strong operational execution in 2025, QIAGEN enters 2026 with plans for new product launches and submissions among its pillars designed to expand add.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. QIAGEN announced in November 2025 plans for the repurchase, which comes after QIAGEN has returned about $650 million to shareholders since the start of 2024 through a synthetic.

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Qiagen N.V. ( QGEN ) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion November 21, 2025 9:00 AM EST Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Michael Scheffler Nitin Sood - Senior VP & Head of Product Portfolio & Innovation Fernando Beils Justus Krause-Harder Presentation Domenica Martorana Associate Director of Global Investor Relations Welcome to our next QIAGEN Deep Dive.

Qiagen N.V. ( QGEN ) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Welcome, everybody.

Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) climbed 7% to 1.93p after the company unveiled a collaboration with Qiagen designed to bring its Parsortix circulating tumour cell platform to a wider range of pharmaceutical partners. The agreement gives Qiagen the ability to bundle Parsortix into projects alongside its own molecular technologies, including polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing.